Clinical TrialsPRAX-628 leads a promising and novel epilepsy pipeline, with a 100% response rate in treated patients in the phase 2 proof-of-concept study.
EarningsThe cash balance at the end of Q2 was $433.8MM, which should support cash runway into 2027.
Product DevelopmentPraxis is now planning to initiate four Phase 2/3 studies as part of the PRAX-628 Energy program for both regulatory approval and explore the drug's efficacy in generalized epilepsy patients.